<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-531
Date of Submission: 2025-02-22

This report was submitted by a Pharmacist from Yang, Casey and Gill Medical Center concerning patient ANON-PX-6125. The subject is an adult female with a significant medical history including coronary artery disease, chronic kidney disease, anxiety, osteoarthritis. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Atorvastatin (Statin) administered via the Intramuscular route at a dosage of 105mg, initiated on 2025-01-23 for Hypercholesterolemia and discontinued on 2025-02-13; Gabapentin (Anticonvulsant) administered via the Subcutaneous route at a dosage of 162mg, initiated on 2025-01-23 for Neuropathic pain and discontinued on 2025-02-13.

On approximately 2025-01-25, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Hepatotoxicity, Stevens-Johnson syndrome. The Hepatotoxicity was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Stevens-Johnson syndrome was classified as Mild in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 1 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Ball thing commercial attack investment. Summer add report old. Ten listen need health kind choose.</data>
report_id: ADR-2025-531
report_date: '2025-02-22'
patient_details:
  patient_id: ANON-PX-6125
  gender: Female
  relevant_history:
  - coronary artery disease
  - chronic kidney disease
  - anxiety
  - osteoarthritis
suspected_drugs:
- drug_name: Atorvastatin
  dosage: 105mg
  route_of_administration: Intramuscular
  start_date: '2025-01-23'
  indication_for_use: Hypercholesterolemia
  drug_class: Statin
  end_date: '2025-02-13'
- drug_name: Gabapentin
  dosage: 162mg
  route_of_administration: Subcutaneous
  start_date: '2025-01-23'
  indication_for_use: Neuropathic pain
  drug_class: Anticonvulsant
  end_date: '2025-02-13'
adverse_reactions:
- symptom_name: Hepatotoxicity
  onset_date: '2025-01-25'
  severity: Severe
  outcome: Unknown
  intervention_required: false
- symptom_name: Stevens-Johnson syndrome
  onset_date: '2025-01-25'
  severity: Mild
  outcome: Recovered
  intervention_required: true
causality_assessment:
  assessment_conclusion: Possible
  dechallenge_rechallenge: Not applicable
  naranjo_score: 1
reporting_facility: Yang, Casey and Gill Medical Center
reporter_type: Pharmacist
notes: Ball thing commercial attack investment. Summer add report old. Ten listen
  need health kind choose.
